Bioavailability, Genotoxicity and In-Vivo - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

Genotoxicity

In-Vivo

The Composition and Value of a Portfolio Analysis

Camargo

DECEMBER 22, 2021

Clinical pharmacology may also involve comparative bioavailability analyses, which are generally required for drug formulation bridging studies, to demonstrate bioequivalence. Gaining a thorough understanding of these factors can significantly impact development strategy and increase the likelihood of marketplace success.

Bioequivalency

Bioequivalency Production Genotoxicity In-Vivo

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

MARCH 8, 2021

This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We

Trials

Trials In-Vivo Genotoxicity RNA

The Composition and Value of a Portfolio Analysis

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Stay Connected